Business Context and Reporting Period
Xencor, Inc. (XNCR) filed a Form 8-K on July 29, 2026, reporting the entry into a material definitive agreement. The filing addresses a commercial dispute resolution with Alexion Pharma International Operations Limited regarding U.S. royalties on the drug Ultomiris (ravulizumab-cwvz).
Key Financial Metrics
- Settlement Proceeds: The Company will receive an aggregate of $105 million.
- Payment Schedule: Two equal payments of $52.5 million each. The first is anticipated in August 2026; the second is due within 14 days of the one-year anniversary of the agreement.
- Liquidity Outlook: Management expects sufficient cash to fund research and development programs and operations through 2028.
- Revenue Impact: The filing does not provide specific revenue, profit, or margin figures for the current period. It notes that Alexion will have no further obligation to pay royalties on U.S. sales of Ultomiris, though ex-U.S. royalty obligations remain unchanged.
Material Changes
The primary material change is the resolution of a dispute initiated in March 2026, when Alexion stated it did not intend to make future royalty payments on U.S. sales. The Settlement Agreement fully resolves this matter, converting uncertain future royalty claims into a fixed $105 million settlement. This agreement terminates future U.S. royalty obligations from Alexion while preserving existing terms for ex-U.S. sales.
Guidance, Outlook, and Risks
Outlook: The Company maintains its operating plan to fund operations through 2028 based on current cash positions and the settlement proceeds.
Risks and Contingencies: The filing notes that the description of the Settlement Agreement is qualified by reference to the full text, which will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026, or via amendment. There are no other specific risks or unusual items detailed in this report beyond the resolution of the royalty dispute.
Investor Verification Checklist
- Verify the receipt of the first $52.5 million payment in August 2026.
- Review the full text of the Settlement Agreement when filed as an exhibit to the Q3 2026 Form 10-Q for detailed terms and conditions.
- Monitor future quarterly reports to confirm the cessation of U.S. royalty revenue from Ultomiris and the continuation of ex-U.S. royalties.
- Assess the impact of the $105 million inflow on the Company's cash runway extending through 2028.